

---

## Press Release

### Contact

Virginia Cancer Specialists  
Michelle Keene  
T 571-499-1914  
[michelle.keene@usoncology.com](mailto:michelle.keene@usoncology.com)

## Medical Oncologist and Leader Named Advocacy Champion by the American Society of Clinical Oncology

**FAIRFAX, Va., January 11, 2019**— The American Society of Clinical Oncology ([ASCO](#)) named its President’s Circle Advocacy Champions for 2017 during its 2018 Advocacy Summit on Capitol Hill. Among those recognized was [Neelima Denduluri, MD](#), medical oncologist with Virginia Cancer Specialists ([VCS](#)) and the associate chair of the Breast Cancer Research Committee for [The US Oncology Network](#).

“ASCO congratulates and commends this year’s advocacy champions for their work to make Congress aware of the challenges oncologists and the cancer care community face in providing high-quality cancer care,” said ASCO Government Relations Committee Chair Jeffery C. Ward, MD, FASCO. “The efforts of these dedicated volunteers have and will continue to help ASCO push for policies that ensure high-quality, high-value care for cancer patients everywhere.”

Throughout the past year, Dr. Denduluri has participated in ASCO’s One Voice Against Cancer Hill Day in Washington D.C., met with multiple U.S. senators and representatives who represented different states, sent many letters raising awareness and educating representatives on cancer breakthroughs and concerns, and cultivated awareness of the ASCO ACT Network nationwide on social media and through networking opportunities.

“Joining my fellow oncologists in an effort to educate lawmakers about cancer care is important work,” said Dr. Denduluri. “We’re on the front lines of treating patients and come together from across the U.S. in support of quality medicine and making it more accessible to patients nationwide.”

###

### About Virginia Cancer Specialists

For more than 40 years, VCS has contributed to the campaign against cancer and diseases of the blood. VCS has nine locations throughout Northern Virginia staffed by highly-skilled physicians, each delivering exceptional care. The practice has built a world-class treatment team of cancer specialists, as well as acquiring the very latest treatment technology to help achieve the best outcomes for patients. VCS unites medical and radiation oncologists, breast and musculoskeletal surgeons, hematologists, palliative care physicians, oncology nurse navigators, oncology infusion nurses, radiation therapists, genetic counselors, oncology pharmacists and laboratory technicians. All working together, this team designs the optimal multidisciplinary treatment program, efficiently shares knowledge, executes the treatment plan, and provides a patient-centered, consumer-friendly approach to cancer care. Patients receive the full spectrum of high-quality care necessary to treat their disease from a care team united in their effort to provide each patient with the specific personalized care they need to battle cancer. The physicians at VCS have published more than 100 abstracts and papers over the last few years and have been invited to present at national meetings. To learn more about Virginia Cancer Specialists, please visit [www.VirginiaCancerSpecialists.com](http://www.VirginiaCancerSpecialists.com).

Virginia Cancer Specialists is a practice in [The US Oncology Network](#) (The Network). This collaboration unites VCS with more than 1,400 independent physicians dedicated to delivering value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing

## Press Release

local cancer care and to delivering better patient outcomes. The US Oncology Network is supported by [McKesson Corporation](#), whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. VCS also participates in clinical trials through [US Oncology Research](#), which has played a role in more than 75 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date.